patients with the anterior circulation and a minor stroke who experienced an END and LVO
Conditions
Interventions
EVT:endovascular treatment
BMT:medical treatment
Sponsors
Yijishan Hospital of Wannan Medical college
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: General Inclusion Criteria: (1) Age >= 18 years old; (2) The initial onset of the disease is consistent with the diagnosis of mild ischemic stroke, with a NIHSS score of less than 6; (3) Symptom progression: During progression, the NIHSS score increases by >= 4 points compared to the initial NIHSS score; (4) The progression time of symptoms is within 7 days of the first onset; (5) The time from initial onset to randomization is greater than 24 hours; The first onset includes wake up stroke; The onset time refers to the patient's last known well (LKW); (6) Symptoms progress to randomization time = 6 points before randomization; (8) The patient or legal representative is willing to comply with the protocol requirements and data collection procedures, understand and sign the informed consent form. Specific Neuroimaging Inclusion Criteria: (1) CTA or MRA proved occlusion of Internal Carotid Artery (ICA) terminal or M1 segment of Middle Cerebral Artery; (2) The progression of symptoms is caused by the recurrence of cerebrovascular diseases in the same vascular region, or the pathogenesis is caused by reduced blood flow perfusion; (3) NCCT ASPECTS before randomization = 6; (4) CTP or MRP assessment shows low perfusion in the target vessel area, and meets the following criteria: core infarction volume is less than 50ml, mismatch rate is greater than or equal to 1.8, and mismatch volume is greater than 15ml.
Exclusion criteria
Exclusion criteria: 1. Pre-stroke mRS score >1; 2. Imaging confirms the progression of symptoms caused by intracranial hemorrhage, brain edema, or other clear causes; 3. The target vessel may have factors that may prevent it from completing endovascular treatment, such as a diameter less than 1.5mm, a tortuous vascular pathway, difficulty in reaching the target position with instruments, or difficulty in recovery; 4. Severe stenosis or occlusion of multiple blood vessels; 5. Combined with untreated intracranial aneurysms, intracranial tumors (excluding small meningiomas), or intracranial vascular malformations; 6. Intracranial hemorrhage within 6 months, including cerebral parenchymal hemorrhage, ventricular hemorrhage, and subarachnoid hemorrhage; 7. Have had gastrointestinal or urinary system bleeding, acute myocardial infarction, traumatic brain injury, or undergone major surgical procedures within the past month; 8. Known hemorrhagic tendency (including but not limited to): Baseline platelet count 2 (Patients with no history or suspected coagulopathy do not need to wait for laboratory results of INR or APTT prior to enrollment); 9. Severe heart, liver, kidney function damage or other severe late stage diseases of the system; 10. Known allergies to treatment related drugs such as iodine contrast agents, etc; 11. Known severe allergy (more than a rash) to contrast media uncontrolled by medications; 12. Refractory hypertension (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg); 13. Uncontrolled blood sugar abnormalities (less than 2.8mmol/l or greater than 22.2mmol/l); 14. Females who are pregnant, or those of child-bearing potential with positive urine or serum beta Human Chorionic Gonadotropin (HCG) test; 15. The expected survival time is less than 1 year (such as complicated with malignant tumor, serious heart and lung diseases, etc.) ? Participation in other interventional randomized clinical trials that may confound outcome assessment of the trial; 16. Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders);
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| favorable outcome mRS0-2;symptomatic intracerebral haemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| mRS shift analysis;outcome mRS0-3;EQ-5D-5L score;The infarct-core volume;mortality;any intracerebral haemorrhage;favorable outcome mRS0-2; | — |
Countries
China
Contacts
Public ContactZhiming Zhou
Yijishan Hospital of Wannan Medical college
Outcome results
None listed